Paper42344690
Case Report: Alectinib and CNS-directed therapy for primary or relapsed ALK-positive anaplastic large cell lymphoma with central nervous system involvement.
Mikalonytė M and 16 others. Front Oncol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Case Report: Alectinib and CNS-directed therapy for primary or relapsed ALK-positive anaplastic large cell lymphoma with central nervous system involvement. Papers, record 42344690. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42344690
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Case Report: Alectinib and CNS-directed therapy for primary or relapsed ALK-positive anaplastic large cell lymphoma with central nervous system involvement.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References33
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30687633 | ALK Inhibitors in the Treatment of ALK Positive NSCLC. | Front Oncol | 2018 | https://conductscience.org/library/papers/30687633 | PubMed |
| 2 | 40921094 | Anaplastic lymphoma kinase-positive primary CNS anaplastic large cell lymphoma in a pediatric patient: illustrative case. | J Neurosurg Case Lessons | 2025 | https://conductscience.org/library/papers/40921094 | PubMed |
| 3 | 30992232 | Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib. | Clin Lymphoma Myeloma Leuk | 2019 | https://conductscience.org/library/papers/30992232 | PubMed |
| 4 | 28974506 | Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. | Blood | 2017 | https://conductscience.org/library/papers/28974506 | PubMed |
| 5 | 38865667 | Brigatinib in ALK-Positive ALCL after Failure of Brentuximab Vedotin. | N Engl J Med | 2024 | https://conductscience.org/library/papers/38865667 | PubMed |
| 6 | 23109692 | Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/23109692 | PubMed |
| 7 | 17519389 | Pathobiology of ALK+ anaplastic large-cell lymphoma. | Blood | 2007 | https://conductscience.org/library/papers/17519389 | PubMed |
| 8 | 25153538 | Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. | Lancet Oncol | 2014 | https://conductscience.org/library/papers/25153538 | PubMed |
| 9 | 15800313 | Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. | J Clin Oncol | 2005 | https://conductscience.org/library/papers/15800313 | PubMed |
| 10 | 28459613 | Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/28459613 | PubMed |
| 11 | 26753004 | ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. | Ther Adv Med Oncol | 2016 | https://conductscience.org/library/papers/26753004 | PubMed |
| 12 | 26736010 | Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib. | N Engl J Med | 2016 | https://conductscience.org/library/papers/26736010 | PubMed |
| 13 | 32420302 | Central nervous system relapse in a pediatric anaplastic large cell lymphoma patient with CLTC/ALK translocation treated with alectinib: A case report. | World J Clin Cases | 2020 | https://conductscience.org/library/papers/32420302 | PubMed |
| 14 | 34132378 | Traditional and emerging therapies for anaplastic large cell lymphoma (Review). | Int J Oncol | 2021 | https://conductscience.org/library/papers/34132378 | PubMed |
| 15 | 31226541 | Central nervous system relapse of systemic ALK-rearranged anaplastic large cell lymphoma treated with alectinib. | Leuk Res | 2019 | https://conductscience.org/library/papers/31226541 | PubMed |
| 16 | 23061678 | Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma. | Leuk Lymphoma | 2013 | https://conductscience.org/library/papers/23061678 | PubMed |
| 17 | 35373356 | Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition. | J Clin Pharmacol | 2022 | https://conductscience.org/library/papers/35373356 | PubMed |
| 18 | 18385450 | ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. | Blood | 2008 | https://conductscience.org/library/papers/18385450 | PubMed |
| 19 | 40672809 | Involvement of the central nervous system in relapsed T-cell lymphoma: insights from four case studies. | Leuk Res Rep | 2025 | https://conductscience.org/library/papers/40672809 | PubMed |
| 20 | 9166827 | A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. | Blood | 1997 | https://conductscience.org/library/papers/9166827 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| ALK | 238 | PubTator's text mining | https://conductscience.org/library/genes/238 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42344690
GET https://conductscience.org/api/papers/v1/42344690/references?page=2